semaglutide alzheimer's disease clinical trial Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic (evoke and evoke+): two phase 3, randomised, placebo-controlled trials semaglutide alzheimer's clinical trial evoke

Health Canada's standard 180-day review timeline for generic applications means the first approvals could arrive as early as mid-2026, though complex submissions may require additional review time

Researchers Link Use of GLP-1 Medications to Lower Risk of Violence A Rutgers study finds that treatments such as Ozempic and Wegovy may diminish the link between impulsivity and violent behavior The use of GLP-1 medications commonly prescribed for weight loss or managing diabetes may have effects that extend beyond metabolic health, including on behaviors linked to violence, according to Rutgers researchers

Goodrx are preparing their angus

Terms & Conditions are located in our Impact Program Terms.

Tirzepatide should not be used during pregnancy and there may be potential risks to an unborn baby from exposure to tirzepatide during pregnancy